Cardiovascular Systems (CSII) Stock Price

Cardiovascular Systems Price

NASDAQ·CLOSED
0
​
Market closed

Over the last 18 years Cardiovascular Systems grew revenue by 37.9% annually, reaching 236.22 M USD. For Cardiovascular Systems, the net margin of -15.6% is down versus 0.8% a few years ago.

Cardiovascular Systems stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cardiovascular Systems business model & stock analysis

Cardiovascular Systems Inc. (CSI) is a US medical technology company founded in 1989. The company is headquartered in St. Paul, Minnesota and employs approximately 1,000 employees worldwide. CSI develops, manufactures, and distributes innovative devices for the treatment of vascular diseases. The business model of CSI is based on the development and marketing of medical devices for minimally invasive treatment of vascular diseases. The company generates a significant portion of its revenues through the sale of its products to hospitals and specialized healthcare facilities. Additionally, CSI also offers training and educational programs for doctors and medical personnel to optimize the use of their devices. CSI operates in two main segments: peripheral arterial disease (PAD) and coronary heart disease (CHD). The PAD segment includes devices for the treatment of vascular diseases outside of the heart, such as peripheral arterial occlusive disease (PAOD). This includes the Diamondback-360® catheter and the Stealth 360® catheter, both used for plaque ablation in the arteries. The CHD segment focuses on the treatment of heart diseases such as coronary artery disease (CAD). This includes the Orbital Atherectomy System (OAS), a device that can reduce the use of stents in patients with more severe coronary artery narrowings. CSI's core product is the Diamondback-360® catheter, which was approved by the US Food and Drug Administration (FDA) in 2013. This device consists of a rotating catheter inserted into the artery to remove plaque causing vessel narrowing. The Diamondback-360 catheter is used for the treatment of PAD and has the potential to significantly improve patients' quality of life. Another important product from CSI is the Orbital Atherectomy System (OAS), used for the treatment of CAD. The OAS system is a rotating catheter that can remove plaque in the coronary arteries to improve blood flow. The use of OAS can potentially avoid costly and invasive procedures such as coronary angiography or bypass. In summary, Cardiovascular Systems Inc. is a leading company in the development and production of innovative devices for minimally invasive treatment of vascular diseases. The company specializes in two main segments, peripheral arterial disease and coronary heart disease. With products like the Diamondback-360 catheter and the Orbital Atherectomy System, CSI has established itself as a reliable provider of high-quality medical devices. Through training and educational programs, CSI also contributes to improving medical care and the development of treatment methods.

Frequently asked questions about Cardiovascular Systems

The business model of Cardiovascular Systems Inc (CSI) is focused on developing and commercializing innovative solutions for treating peripheral and coronary artery diseases. CSI specializes in developing and manufacturing medical devices that address complex vascular diseases through its unique orbital atherectomy technology. This technology allows for precise removal of plaque in arterial vessels, restoring blood flow and improving patient outcomes. CSI's business model revolves around providing effective and minimally invasive treatment options to healthcare professionals, while continually investing in research and development to drive future growth and enhance patient care.

Cardiovascular Systems Inc primarily operates in the medical device industry, specifically focusing on the treatment of peripheral arterial disease (PAD). As a leading medical technology company, Cardiovascular Systems Inc develops and sells innovative solutions to healthcare professionals, specializing in minimally invasive treatment options for patients with PAD. With a strong presence in the cardiovascular field, Cardiovascular Systems Inc continues to make significant advancements in improving patient outcomes and quality of life.

The main competitors of Cardiovascular Systems Inc in the market are Medtronic, Boston Scientific Corporation, Abbott Laboratories, and AngioDynamics Inc.

Cardiovascular Systems Inc (CSI) is a renowned medical device company specializing in developing and commercializing innovative solutions for treating vascular diseases. Established in 1989, CSI has been at the forefront of revolutionizing the field of interventional cardiology. From humble beginnings in Minnesota, the company has grown to become a global leader in providing cutting-edge technologies for treating complex calcium and arterial plaque build-up. With a strong commitment to improving patient outcomes, CSI offers a range of products such as orbital atherectomy systems and coronary, peripheral, and vascular support devices. Through continuous research and development, CSI remains dedicated to advancing cardiovascular care worldwide.

Cardiovascular Systems Inc has achieved significant milestones in its journey. Some noteworthy achievements include the FDA clearance of its Diamondback 360® System for treating coronary artery disease, the successful completion of the ORBIT II clinical trial, and the introduction of its Diamondback Predator 360® for the peripheral artery disease market. Furthermore, the company has consistently expanded its product portfolio, focusing on innovative technologies and enhancing patient outcomes. Cardiovascular Systems Inc has also received recognition and accolades for its contributions to the medical device industry, establishing itself as a trusted name in the field of cardiovascular care.

Cardiovascular Systems Inc (CSI) is primarily present in the United States. As a leading medical device company focused on treating peripheral and coronary artery disease, CSI operates in various states across the U.S. including Arizona, California, Florida, Georgia, Illinois, New York, Texas, and many more. With its innovative solutions and dedicated medical professionals, CSI has expanded its presence throughout the country, offering its advanced technologies and therapies to healthcare providers and patients alike.

Cardiovascular Systems Inc (CSI) represents values of excellence, innovation, and patient-centric care. As a leading medical device company, CSI focuses on developing and commercializing innovative solutions for treating peripheral and coronary arterial diseases. With a mission to improve patient outcomes and quality of life, CSI is guided by a corporate philosophy rooted in continuous research, clinical evidence, and collaboration with healthcare professionals. By offering cutting-edge technologies and therapeutic strategies, CSI strives to revolutionize the field of cardiovascular medicine.

12 analysts currently rate the Cardiovascular Systems stock: 0 recommend buying, 7 holding and 5 selling.

The Cardiovascular Systems share (CSII) is listed on 3 stock exchanges, including: NASDAQ (CSII), Frankfurt (R7Y1.F), München (R7Y1.MU).

The company Cardiovascular Systems Inc (CSI) is a medical technology company specializing in innovative solutions for the treatment of vascular diseases. CSI's mission is to provide patients worldwide with a better quality of life through advanced technologies and therapeutic solutions. CSI offers a wide range of products and services to treat various vascular diseases. The main products include Orbital Atherectomy Systems (OAS), equipped with razor-sharp diamond crowns to remove calcifications and plaques from blocked arteries and improve blood flow. OAS systems are also used to treat severe cases of peripheral arterial disease (PAD) and coronary heart disease (CHD). CSI also provides a variety of training and support services to help doctors and medical professionals familiarize themselves with OAS systems and other products. The training includes practical instructions, live webinars, and hands-on workshops led by experienced healthcare professionals. Another important area of CSI's business is research and development of new products and technologies to continuously develop innovative solutions for the treatment of vascular diseases. The company has a worldwide network of research centers and clinics that collaborate closely with leading medical technology companies, university hospitals, and medical research groups. CSI works closely with health authorities and medical societies to ensure that all products and services meet the highest standards of patient safety and effectiveness. The company has obtained approvals and certifications from various regulatory agencies worldwide, including the FDA, the European Union, and the Japanese health authority. CSI's business model is based on providing highly innovative solutions for the treatment of vascular diseases and collaborating with doctors, medical professionals, and researchers to improve patient care. The company has a strong presence in the US and Europe and is now expanding to other parts of the world such as Asia, Australia, and Latin America. Overall, CSI offers an extensive portfolio of products and services for the treatment of vascular diseases and has established itself as one of the leading companies in this field. Through continuous innovation, collaboration with professionals, and adhering to the highest standards of safety and effectiveness, CSI strives to improve healthcare for patients worldwide.

The revenue cannot currently be calculated for Cardiovascular Systems.

The profit cannot currently be calculated for Cardiovascular Systems.

The P/E ratio cannot be calculated for Cardiovascular Systems at the moment.

The P/S cannot be calculated for Cardiovascular Systems currently.

The Eulerpool Quality Score for Cardiovascular Systems is 4/10.

The ISIN of Cardiovascular Systems is US1416191062. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Cardiovascular Systems is A0RF8V. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Cardiovascular Systems is CSII. The ticker symbol is used to trade Cardiovascular Systems shares on the stock exchange.

Fair ValueTerminal
148.30 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
323,149.11 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website csi360.com
Currency
USD
Initial public offering
Jun 28, 2006
ISIN
US1416191062
Cusip
141619106
Sedol
B17HG57
Market capitalization
839.18 M USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2023
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
3.36
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-13.69 %
Last updated Nov 16, 2026, 12:21 PM

Cardiovascular Systems Ticker

FRANKFURT · R7Y1.FMUNICH · R7Y1.MUNASDAQ · CSII

Cardiovascular Systems FIGI

CSIIEUR:XB · BBG00J41LKB1CSIIEUR:XS · BBG00J41LKS3CSIIUSD:XB · BBG00JRQNPY3CSIIUSD:XS · BBG00JRQNQD4CSIIGBP:XB · BBG00K6CJZZ6CSIIGBP:XS · BBG00K6CK0F3

All fundamentals and in-depth analysis of Cardiovascular Systems

Our stock analysis for Cardiovascular Systems stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cardiovascular Systems. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.